If you game biotech you might want to make sure that Alkermes is on your radar.

The company may stand to profit more than expected from the approval of once a week Byetta – a diabetes drug its developing in partnership with Eli Lilly and Amylin Pharmaceuticals.

What must you know?

Find out from Alkermes CEO Richard Pops. Watch the video now!